Author: F. Michael Haller, PhD, Principal Scientist, R&D

Abstract:

One major obstacle to achieving shortened development times and reduced costs of adeno-associated gene therapy products is the lack of standardized and cGMP-compliant downstream purification platforms. Besides providing high yields and purities, such platforms should be applicable to a wide variety of AAV serotypes as well as being customizable with minimal process modifications to allow rapid development of scalable downstream purification processes for clinical testing. Previously, we developed a comprehensive AAV production platform consisting of a proprietary high-producer suspension HEK293 cell line, a high-performing packaging plasmid system and an optimized triple transfection-based upstream process. In this study, we developed a streamlined downstream purification process using a GFP-encoding AAV9 construct (AAV9-GFP) as model. The applicability of the process was subsequently verified for several other AAV serotype/GOI combinations. For AAV9-GFP, the total process recovery was up to 38 %, starting from unclarified cell lysate at 3 L bioreactor scale, with post lysis titers of ~1.0 E+15 vg per liter cell culture by ddPCR titer assay. After affinity capture, circa 60 % full capsid content were obtained, which could be further enriched to up to 74-90% full, based on AUC capsid only quantification and/or SEC-MALS or mass photometric analyses. For an AAV9 model construct encoding a therapeutically relevant protein (AAV9-GOI1), a post-lysis intact genomic titer by 2D ddPCR of 4.1E+14 vg per liter production scale was achieved. After affinity capture, a Full:Empty ratio of 1.1 was obtained which increased to 11.5 for the BDS, with the final product containing 86 % full and less than 8 % empty capsid (AUC capsid only quantification). Starting from crude cell lysate, an overall downstream process yield of 33 % was obtained, while residual host cell DNA was reduced to below 2.5 ng/E+12 vg and HCP levels below the assay’s lower limit of quantification. In conclusion, we developed a streamlined AAV downstream purification process with high total recovery and full% capsid content of the final product at high levels of purity.

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center